AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
Completed
- Conditions
- HypercholesterolemiaCardiovascular DiseasePeripheral Arterial DiseaseHypertensionCoronary Heart DiseaseDiabetes
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1236
- Registration Number
- NCT01768403
Roflumilast Plus Montelukast in Adults With Severe Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT01765192
Canadian Ticagrelor Survey
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2012-12-31
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 244
- Registration Number
- NCT01757483
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
Phase 3
Completed
- Conditions
- Bleeding Peptic Ulcer
- Interventions
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239
- Registration Number
- NCT01757275
- Locations
- 🇨🇳
Research Site, Xian, China
A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient
Phase 3
Withdrawn
- Conditions
- Coronary Heart Disease
- Interventions
- Drug: 90 mg Ticagrelor
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01757262
A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus(T2DM)
- Interventions
- Drug: Mertformin XR 2 x 500 mg
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT01755494
- Locations
- 🇨🇳
Research Site, Beijing, China
A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo to match
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 57
- Registration Number
- NCT01754844
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Korean Post-marketing Surveillance for Kombiglyze XR®
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 755
- Registration Number
- NCT01754142
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Perception of Symptom Variability in COPD
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1058
- Registration Number
- NCT01753427
- Locations
- 🇨🇳
Research Site, Tianjin, Tianjin, China
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Phase 2
Completed
- Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 212
- Registration Number
- NCT01750281
- Locations
- 🇵🇱
Research Site, Szczecin, Poland